InsiderSignal.AI

InsiderSignal.ai

JSPR - Jasper Therapeutics, Inc.

Insider Purchase by Wiggans Thomas G (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Wiggans Thomas G, serving as Dir at Jasper Therapeutics, Inc. (JSPR), purchased 41,000 shares at $2.43 per share, for a total transaction value of $99,630.00. Following this transaction, Wiggans Thomas G now holds 46,000 shares of JSPR.

This purchase represents a 820.00% increase in Wiggans Thomas G's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, September 22, 2025 and publicly disclosed via SEC Form 4 filing on Wednesday, September 24, 2025, 2 days after the trade was made.

Jasper Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Wiggans Thomas G

Dir

Thomas G. Wiggans is a seasoned biopharmaceutical executive serving as a Director at Jasper Therapeutics, Inc. (JSPR), where he has engaged in recent insider trading activities.[[2]](https://insiderinsights.com/free/index.php?s=filer&o=-1&a=&q=WIGGANS+THOMAS+G)[[5]](https://www.insider-monitor.com/trader/cik1208907.html)[[6]](https://jaspertx.com/team-members/thomas-wiggans-chair/) With over 40 years of leadership experience, he co-founded Dermira, Inc. in 2010 and served as CEO and Chairman until its acquisition by Eli Lilly in 2020.[[1]](https://annexonbio.com/team/thomas-g-wiggans/)[[3]](https://www.gurufocus.com/insider/68368/thomas-g-wiggans)[[4]](https://fintool.com/app/research/companies/ANNX/people/thomas-wiggans) Previously, he was CEO and Chairman of Peplin, Inc. (acquired by LEO Pharma in 2009) and Connetics Corporation (acquired by Stiefel Laboratories in 2006), and held senior roles at CytoTherapeutics Inc., Ares-Serono S.A., and Eli Lilly & Company.[[1]](https://annexonbio.com/team/thomas-g-wiggans/)[[4]](https://fintool.com/app/research/companies/ANNX/people/thomas-wiggans)[[6]](https://jaspertx.com/team-members/thomas-wiggans-chair/) Mr. Wiggans currently chairs the boards of Annexon, Inc. (since 2021) and Jasper Therapeutics, and has served on boards including Forma Therapeutics (acquired by Novo Nordisk in 2022), CymaBay Therapeutics (acquired by Gilead in 2024), Onyx Pharmaceuticals (acquired by Amgen in 2013), and others.[[1]](https://annexonbio.com/team/thomas-g-wiggans/)[[3]](https://www.gurufocus.com/insider/68368/thomas-g-wiggans)[[4]](https://fintool.com/app/research/companies/ANNX/people/thomas-wiggans)[[6]](https://jaspertx.com/team-members/thomas-wiggans-chair/) He holds a B.S. in Pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University, and his estimated net worth exceeds $5 million as of recent filings.[[3]](https://www.gurufocus.com/insider/68368/thomas-g-wiggans)[[4]](https://fintool.com/app/research/companies/ANNX/people/thomas-wiggans)

View full insider profile →

Trade Price

$2.43

Quantity

41,000

Total Value

$99,630.00

Shares Owned

46,000

Trade Date

Monday, September 22, 2025

153 days ago

SEC Filing Date

Wednesday, September 24, 2025

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Jasper Therapeutics, Inc.

Company Overview

No company information available
View news mentioning JSPR

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/476523

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime